CoreCap Advisors’s AnaptysBio ANAB Stock Holding History

CoreCap Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-31	Closed	-$576	–	2780
2025 Q1	$576	Buy	+31	New	+$517	﹤0.01%	2649

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

CoreCap Advisors's ANAB Position: Q2 2025 in Review

CoreCap Advisors sold out of AnaptysBio (ANAB) in Q2 2025, closing a stake of 31 shares — an estimated $576 sold.

CoreCap Advisors first reported a position in ANAB in Q1 2025 and held it in 1 quarter. The position peaked at $576 in Q1 2025. 147 funds tracked by Wall St. Rank hold ANAB as of Q2 2025.

CoreCap Advisors reported no remaining AnaptysBio position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 31 AnaptysBio shares in Q2 2025, an estimated $576.
CoreCap Advisors first reported a position in AnaptysBio in Q1 2025 and held it in 1 quarter.
CoreCap Advisors's AnaptysBio position peaked at $576 in Q1 2025.
147 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.